Directorio de personas
Antonia Salud Salvia

Antonia Salud Salvia

Grado: Doctor/a


masalud.lleida.ics(ELIMINAR)@gencat.cat

OrcidID: https://orcid.org/0000-0002-7399-7484

Grupos

Publicaciones

  • Mulet, MT; Rodriguez, JV; Teran, E; Pinol, M; VILARDELL, F; Iglesias, M; Hierro, C; Calvo, M; Matias-Guiu, X; Salud, A; Tabernero, J; Montal, R

    Biomarker-guided immunotherapy in gastric cancer: current insights and future perspectives

    CANCER TREATMENT REVIEWS 145 103124-103124. .

    [doi:10.1016/j.ctrv.2026.103124]

  • Porcel J.M.; Hidalgo I.; Marqués M.; Parisi E.; Esquerda A.; Farré C.; Salud A.; Sorolla M.A.

    Pleural Fluid Outperforms Plasma for Detection of Clinically Relevant Mutations in Lung Cancer-Associated Malignant Pleural Effusion

    ARCHIVOS DE BRONCONEUMOLOGIA -. .

    [doi:10.1016/j.arbres.2026.05.009]

  • Toledano-Fonseca, M; Cano-Osuna, MT; Elez, E; Soto-Alsar, J; Paáez, D; Fernández-Montes, A; Graña, B; Salud, A; Yubero, A; Macías, I; Quintero, G; López-López, C; Fernández-Rodríguez, T; García-Ortiz, MV; Sastre, J; García-Alfonso, P; Rodríguez-Ariza, A; Aranda, E

    Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients

    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 56 -. .

    [doi:10.1111/eci.70103]

  • Munavvar, M; Bodtger, U; Carus, A; Cordovilla, R; Naik, S; Salud, A; Porcel, JM

    Current Trends in Treating Malignant Pleural Effusion: Evidence, Guidelines, and Best Practice Recommendations

    JCO Oncology Practice 21 759-765. .

    [doi:10.1200/OP.24.00387]

  • Valladares-Ayerbes M; Toledano-Fonseca M; Graña B; Jimenez-Fonseca P; Pulido-Cortijo G; Gil S; Sastre J; Salud A; Rivera F; Salgado M; García-Alfonso P; López López R; Guillén-Ponce C; Rodríguez-Ariza A; Vieitez JM; Díaz-Rubio E; Aranda E

    Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer.

    BMC CANCER 25 743-743. .

    [doi:10.1186/s12885-025-14098-9]

  • Rodriguez, JV; Piñol, M; Sorolla, MA; Parisi, E; Sorolla, A; Santacana, M; Ruiz, M; Parra, G; Bernabeu, M; Iglesias, M; Aracil, C; Escartin, A; Vilardell, F; Matias-Guiu, X; Salud, A; Montal, R

    Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies

    Journal for ImmunoTherapy of Cancer 13 -. .

    [doi:10.1136/jitc-2024-010024]

  • Xu, CM; Mannucci, A; Esposito, F; Oliveres, H; Alonso-Orduña, V; Yubero, A; Fernández-Martos, C; Salud, A; Gallego, J; Martín-Richard, M; Fernández-Plana, J; Guillot, M; Aparicio, J; Fakih, M; Kopetz, S; Feliu, J; Maurel, J; Goel, A

    An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study

    CLINICAL CANCER RESEARCH 31 1002-1015. .

    [doi:10.1158/1078-0432.CCR-24-1934]

  • García-Alfonso, P; Elez, E; Soto-Alsar, J; Páez, D; Fernández-Montes, A; Graña, B; Salud, A; Yubero, A; Gómez-España, MA; Macías, I; Quintero, G; López-López, C; Fernández-Rodríguez, T; Grávalos, C; González-Flores, E; Guix, M; Paredes, BG; Reina, JJ; Mowbray, JRR; Sastre, J; Aranda, E

    Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial

    ESMO Open 9 103986-103986. .

    [doi:10.1016/j.esmoop.2024.103986]

  • Hidalgo, I; Sorolla, MA; Sorolla, A; Salud, A; Parisi, E

    Secreted Phospholipases A2: Drivers of Inflammation and Cancer

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 25 -. .

    [doi:10.3390/ijms252212408]

  • Rodríguez, JV; Prieto, A; Vilaprinyo, E; Bonet, M; Diez, M; Salud, A; Montal, R

    Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis (vol 201, 104416, 2024)

    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 202 104466-104466. .

    [doi:10.1016/j.critrevonc.2024.104466]

  • Rodríguez, JV; Prieto, A; Vilaprinyo, E; Bonet, M; Diez, M; Salud, A; Montal, R

    Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis

    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 201 104416-104416. .

    [doi:10.1016/j.critrevonc.2024.104416]

  • Valladares-Ayerbes, M; Safont, MJ; Flores, EG; García-Alfonso, P; Aranda, E; Muñoz, AML; Ferrer, EF; Nogueras, LC; Rodríguez-Salas, N; Aparicio, J; Muñoz, ML; Cáceres, PPP; Trujillo, OAC; Tocino, RV; Fernández, MS; Salud-Salvia, A; Sureda, BM; Garcia-Carbonero, R; Conesa, MAV; Vila, AL

    Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical & Translational Oncology 26 2640-2651. .

    [doi:10.1007/s12094-024-03487-4]

Proyectos

  • Decodificación de la metástasis del cáncer colorrectal desentrañando el señalosoma de PLA2G12A
  • Biomarcadores de Respuesta a Inmunoterapia mediante la Inmunofenotipificación Exhaustiva del Adenocarcinoma Gástrico.
  • Ajuts per a la contractació de personal investigador novell (FI)
  • Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
  • Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
  • UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante